Evaluate the following distinct adverse clinical outcomes observed in patients receiving pharmacotherapy for bipolar disorder. Match each clinical presentation to the specific psychotropic medication most strongly associated with its development.
- Fetal ultrasound at 18 weeks gestation demonstrating downward displacement of the tricuspid valve leaflets into the right ventricle.Lithium
- Development of a painful, blistering mucocutaneous rash with epidermal detachment spreading across the trunk within two weeks of medication initiation.Lamotrigine
- New-onset lethargy and confusion accompanied by laboratory evidence of severe euvolemic hyponatremia (serum sodium 122 mEq/L) and low serum osmolality.Carbamazepine
- Routine follow-up laboratory testing revealing newly elevated serum transaminases and prolonged prothrombin time, prompting concern for fulminant hepatic necrosis.Valproate
Answer
The correct matches are: tricuspid valve displacement to Lithium; blistering mucocutaneous rash to Lamotrigine; euvolemic hyponatremia to Carbamazepine; and hepatotoxicity to Valproate.
Each mood stabilizer possesses a distinct, high-yield adverse effect profile that dictates clinical monitoring. Lithium is teratogenic (Ebstein anomaly) and causes nephrogenic diabetes insipidus and hypothyroidism. Lamotrigine requires slow titration specifically to mitigate the risk of Stevens-Johnson syndrome. Carbamazepine is a well-known inducer of SIADH, leading to hyponatremia. Valproate carries black-box warnings for hepatotoxicity, pancreatitis, and neural tube defects.
Step-by-Step Solution
Key Concept
Adverse effect profiles and toxicity monitoring of mood stabilizers used in bipolar disorder.